Skip to main content
Clinical Trials/NCT03139201
NCT03139201
Completed
Not Applicable

A Prospective Randomized Controlled Study to Evaluate the Clinical Performance of OxyAqua Silicone Hydrogel Soft Contact Lens

Visco Vision Inc.0 sites36 target enrollmentSeptember 21, 2016
ConditionsMyopia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myopia
Sponsor
Visco Vision Inc.
Enrollment
36
Primary Endpoint
Log MAR visual acuity (VA)
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The objective of this study is to demonstrate that the OxyAqua silicone hydrogel soft contact lens could be prescribed as a supportive care for myopes.

Detailed Description

This is a double blind randomized control study to evaluate a daily disposable contact lens. It is planned to have 30 evaluable subjects at least divided evenly among 3 independent PIs from one hospital. Each PI will enroll 12 subjects at least. The ration of evaluable test subjects to control subjects will be 2 to 1. The study lens will be dispensed randomly to subjects who have normal ocular health and conform to a set of criteria. It is necessary to wear the lens 8 hours a day and 5 days a week at least and follow up for one month (30 days). Data will be collected at baseline, 1 week, 2 week and 4 week of daily disposable modality including Adverse Reactions, Slit-lamp findings and Symptoms, Problems, and Complaints, vision acuity, keratometry change and reason for discontinuation.

Registry
clinicaltrials.gov
Start Date
September 21, 2016
End Date
December 8, 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects should have normal eyes and use no ocular medications. They may have worn contact lenses previously, provided their eyes are shown to be normal at the start of the investigation. A normal eye is defined as having the following characteristics:
  • No anterior segment infection, inflammation or abnormality.
  • No other active ocular or systemic disease that would contraindicate contact lens wear; and
  • No medications that would contraindicate contact lens wear.
  • VA correctable to 0.1 LogMAR or better, with spherical lenses ranging in power from
  • 1.00 to -10.00 D myopia, astigmatism less than 2.00 D
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Provide signed and dated informed consent form.

Exclusion Criteria

  • Have history of allergies that would contraindicate "normal" contact lens wear.
  • Have other active ocular or systemic disease such as, but not limited to: anterior uveitis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermas, keratoconus or type II diabetes, slip lamp findings greater than grade I (such as cornea or interstitial edema).
  • Have medications that would contraindicate contact lens wear.
  • Have had any cornea surgery.
  • Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next 1 month.
  • Any active participation in another clinical trial within 30 days prior to this study.
  • The presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.
  • A history of papillary conjunctivitis that has interfered with contact lens wear.
  • No monocular or monovision fits.

Outcomes

Primary Outcomes

Log MAR visual acuity (VA)

Time Frame: one month

the visual acuity corrected with contact lens could reach 0.1 or better

Secondary Outcomes

  • Any slit lamp findings > grade 2(over all follow-up visits for the 1 month)
  • Subjective response to comfort, symptoms and complaints(over all follow-up visits for the 1 month)

Similar Trials